Anteris Technologies Global Corp. 8-K Filings

Anteris Technologies Global Corp. (AVR) appointed Brent Moen as Chief Financial Officer, effective September 11, 2026, succeeding Matthew McDonnell, who will become Head of Australia and remain an employee under his current compensation and benefits.

Moen’s employment agreement provides an annual base salary of $475,000, a target annual bonus opportunity of up to 50% of base salary (prorated for 2026), and eligibility for long-term incentives and other executive benefit plans. For 2026, the board’s compensation committee approved a long-term incentive award with a target value of $500,000 in nonqualified stock options under the company’s Equity Incentive Plan, with an exercise price equal to the fair market value on the September 11, 2026 grant date. These options vest in three substantially equal annual installments and have a 10-year term.

On a termination by the company without cause, Moen is eligible for nine months of base salary continuation and up to nine months of COBRA premium reimbursement, subject to signing a release. His agreement also includes confidentiality, non-solicitation, invention assignment, and a standard company indemnification agreement.

Anteris Technologies Global Corp. reported first-half 2026 results and provided a business update tied to its DurAVR® Transcatheter Heart Valve program. For the six months ended June 30, 2026, revenue from ordinary activities was $1.503 million, up from $1.174 million a year earlier.

The company recorded a loss from ordinary activities after tax of $51.675 million, compared with $42.993 million in 2025, and a loss attributable to members of $52.118 million. Net operating cash outflows for the quarter were $20.8 million, driven mainly by clinical, regulatory and manufacturing spend for the global pivotal Trial. R&D expenses were $23.4 million, reflecting scaling of manufacturing and quality capabilities and clinical trial activities. Anteris highlighted U.S. Medicare reimbursement for eligible procedures in the Trial and ongoing enrollment across the United States, Europe and Australia.

Anteris Technologies Global Corp. reports that the Federal Court of Australia has granted its application to rectify an inadvertent administrative oversight involving the late lodgement of a cleansing notice under the Corporations Act 2001 (Cth). The matter was heard on 3 August 2026 and the Court granted the relief sought. Anteris has asked the Australian Securities Exchange to lift the trading halt on its securities with effect from market open on 4 August 2026.

On July 31, 2026, Anteris Technologies Global Corp. requested a trading halt in its securities on the Australian Securities Exchange under Listing Rule 17.1 from the commencement of that day’s trading. Trading on The Nasdaq Global Market and The Nasdaq Stock Market is stated to be not impacted.

The company also reports that on July 10, 2026, 44,068 CHESS Depositary Interests (CDIs) were issued following the exercise of certain November 2025 warrants. Due to an administrative oversight, a cleansing notice required under section 708A(6) of the Corporations Act 2001 was not lodged within the prescribed 5 business days. Anteris intends to lodge the cleansing notice now and apply to the Federal Court for relief under section 1322, including an extension of time. The company states that the oversight is not considered price sensitive, that it did not possess excluded information at the time of issue, and that the issued CDIs have been sold.

Anteris Technologies Global Corp. entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) to establish an at-the-market stock offering program. The company may, at its discretion, sell shares of common stock with an aggregate offering price of up to $250,000,000 through TD Cowen as agent or principal.

Sales can be made over time on Nasdaq or through negotiated block trades, with TD Cowen earning a 3.0% commission on gross proceeds from shares it sells as agent. Anteris currently plans to use any net proceeds primarily to fund development of its DurAVR® Transcatheter Heart Valve System, and the remainder for working capital and general corporate purposes.

Anteris Technologies Global Corp. announced that its Board appointed Susan Knight and Stephen Denaro as directors effective May 11, 2026 (May 12, 2026 in Australia). Knight becomes a Class I director with a term running to the 2028 annual meeting and will join the Audit and Risk Committee. Denaro becomes a Class II director with a term running to the 2026 annual meeting. As non-employee directors, they will receive cash retainers and equity compensation under the company’s Non-Employee Director Compensation Policy, including an initial restricted stock unit grant to Knight valued at $250,000, subject to stockholder approval, and potential annual RSU awards valued at $125,000. Denaro also receives an annual fee of AUD $57,645 for serving as company secretary to certain Australian subsidiaries. The company entered into indemnification agreements with both directors, providing protection to the fullest extent permitted under Delaware law.

Anteris Technologies Global Corp. furnished its first-quarter 2026 results, highlighting heavy investment in its pivotal DurAVR heart valve trial. For the three months ended 31 March 2026, net operating cash outflows were $28.7 million, mainly tied to clinical, regulatory and manufacturing work on the Trial.

Research and development expenses were $17.5 million, driven by expanded manufacturing, quality processes, added headcount and clinical costs as more patients were enrolled. The company also reported related-party payments of $2.3 million for director fees and executive compensation during the quarter. The Trial is a ~1,000-patient randomized study comparing the DurAVR transcatheter valve to existing TAVR devices, supported in the U.S. by Medicare and Medicaid coverage under National Coverage Determination 20.32.

Anteris Technologies Global Corp., through its subsidiary Anteris Technologies Corporation, has elected to discontinue additional development contributions under its Contribution and Stock Purchase Agreement with v2vmedtech, inc., following completion of Stage 1 and during Stage 2 of the development program.

As a result, the related Development Agreement dated April 18, 2023 will terminate upon payment of a $400,000 break fee. Anteris states it does not expect this discontinuation of contributions and the termination of the Development Agreement to have a material adverse effect on its consolidated financial position or liquidity.

Anteris Technologies Global Corp. has entered into a long-term lease for approximately 181,436 square feet of office and warehouse space in Brooklyn Park, Minnesota, through its wholly owned subsidiary Anteris Technologies Corporation.

The lease starts on September 1, 2026 and runs through August 31, 2037, with options to extend for two additional 84‑month periods at market rent. Initial monthly minimum rent is $152,708.63, subject to contractual abatements, annual escalations and other adjustments, plus real estate taxes, operating expenses and other charges. Rent is fully abated for the first three months and partially abated for the following nine months, which eases cash outlay during the initial occupancy period.

Anteris Technologies Global Corp. disclosed that its Compensation Committee approved a one-time, discretionary grant of restricted stock units (RSUs) to Chief Financial Officer Matthew McDonnell. The award has a target value of $500,000, with the exact number of RSUs set by the closing price of the Company’s common stock on March 4, 2026, the grant date.

One-third of the RSUs will vest on each of the first three anniversaries of the grant date, contingent on Mr. McDonnell’s continued employment. The RSUs fully vest earlier if he dies, becomes permanently disabled, or experiences certain terminations in connection with a change in control. Once vested, the RSUs will be settled in CHESS depositary interests of the Company and are described as a special award that does not change his 2026 annual equity target.

Anteris Technologies Global Corp. reported weaker 2025 financial results alongside a strategic update on its DurAVR® transcatheter heart valve program. Revenue from ordinary activities was US$1.9 million in 2025, down from US$2.7 million in 2024, a 29% decline as the company focused on clinical development.

The loss from ordinary activities after tax increased to US$94.2 million from US$76.0 million, and loss attributable to members rose to US$94.1 million. Net tangible asset backing per share deteriorated from US$1.74 to (US$0.01) as of December 31, 2025, reflecting accumulated losses. Net operating cash outflows were US$77.8 million, in line with higher clinical, regulatory and manufacturing spend to support its pivotal Trial. The company confirmed that all US$80.0 million of net IPO proceeds raised in December 2024 have been fully used, paid no dividends, and saw no material impact from deregistering two Australian subsidiaries. The Trial has begun enrolling and implanting patients, targeting about 1,000 participants in a head‑to‑head study versus existing TAVR valves.

Anteris Technologies Global Corp. reported that Medtronic plc, through a wholly owned subsidiary, is making a strategic equity investment in the company. The investment is structured under a stock purchase agreement dated January 20, 2026 between Anteris and the Medtronic subsidiary.

On January 22, 2026, Anteris and Medtronic issued a joint press release about this transaction, which is furnished as Exhibit 99.1. The disclosure is provided under Regulation FD, meaning it is intended to share the same information with all market participants at the same time.

Anteris Technologies Global Corp. entered into an underwritten public offering and a concurrent private placement of its common stock. The company agreed to sell 34,782,609 shares in the offering at $5.75 per share, and granted underwriters a 30-day option for 5,217,391 additional shares, which was exercised in full. It also agreed to sell 15,652,173 shares at $5.75 per share in a private placement to Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc.

The combined transactions are expected to generate approximately $320 million in gross proceeds before fees and expenses. Anteris plans to use the net proceeds, together with existing cash, to support its next stage of growth, including the global pivotal PARADIGM Trial for its DurAVR® Transcatheter Heart Valve, expansion of manufacturing capabilities, funding ongoing research and development for v2vmedtech, inc., and for working capital and other general corporate purposes.

Anteris Technologies Global Corp. disclosed that Stephen Denaro resigned from its Board of Directors and as a Class II director, effective December 13, 2025. The company states that his resignation is not due to any disagreement with management or with its operations, policies, or practices, suggesting no underlying dispute at the board level.

Denaro will remain closely involved with the organization as corporate secretary of Anteris Technologies Pty Ltd and as a member of the boards of that company and other Australian subsidiaries. This shifts the composition of the U.S. parent’s board while maintaining leadership continuity within Anteris’s Australian entities.

Anteris Technologies Global Corp. reported that it has presented new clinical information on its DurAVR^® Transcatheter Heart Valve (THV). The company issued an ASX announcement on November 16, 2025 (November 17, 2025 AEDT) and a press release on November 17, 2025 summarizing 30-day clinical outcomes in one hundred severe aortic stenosis patients with small aortic annuli treated with DurAVR THV. This information is being furnished to regulators rather than formally filed, meaning it is shared for transparency but does not carry the same legal status as filed financial statements.

Anteris Technologies Global Corp. (AVR) furnished quarterly results materials. The company submitted an 8-K noting it filed its Form 10-Q for the quarter ended September 30, 2025, and furnished an accompanying ASX Results Announcement and an ASX Announcement. These materials include unaudited and other historical financial information for the quarter. The exhibits (99.1 and 99.2) are furnished under Item 2.02 and are not deemed filed or incorporated by reference unless a later filing expressly states otherwise.

Anteris Technologies Global Corp. furnished a Regulation FD update via Form 8‑K announcing that the U.S. FDA approved its DurAVR® Transcatheter Heart Valve Global Pivotal Trial, known as the PARADIGM Trial. The company attached the related press release as Exhibit 99.1, and the information was furnished, not filed, under the Exchange Act.

Anteris Technologies Global Corp. (AVR) furnished an update via Form 8-K stating that the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve global pivotal PARADIGM trial for severe calcific aortic stenosis.

The company noted this information is being furnished, not filed, under the Exchange Act. An accompanying press release dated October 27, 2025 was included as Exhibit 99.1.

Anteris Technologies Global Corp. (AVR) closed a private common stock offering, issuing 2,346,936 shares of common stock and five-year warrants to purchase 2,346,936 shares, generating approximately US$11.5 million in gross proceeds. The securities were sold at US$4.90 per share with an accompanying warrant, and were issued without registration under Section 4(a)(2) and Rule 506.

The company had earlier expanded the deal by adding 102,040 additional shares on the same terms. The warrants are exercisable commencing six months following the date of issuance. Anteris plans to file a registration statement to cover the resale of the shares and the shares issuable upon exercise of the warrants, as well as CDIs and related warrant shares from a concurrently arranged CDI offering priced at A$7.50 per CDI.

Anteris Technologies Global Corp. (AVR) announced a private placement financing, agreeing to sell 2,244,896 shares of common stock with five-year warrants and 2,788,064 CHESS Depositary Interests (CDIs) with five-year warrants. The common stock is priced at US$4.90 per share and accompanying warrant; the CDIs are priced at A$7.50 per CDI and accompanying warrant. The company expects aggregate gross proceeds of approximately US$25 million.

The common stock offering is expected to close on or around October 27, 2025, and the CDI offering to settle on or around October 30, 2025, subject to customary conditions. Warrants become exercisable six months after issuance, at an exercise price of $7.50 per common share and A$11.50 per CDI. The company will file a registration statement covering the resale of the securities and the shares underlying the warrants and CDIs. The offerings rely on Section 4(a)(2) and Rule 506 of Regulation D (for common stock) and Regulation S (for CDIs). Evolution Capital Pty Ltd, lead manager for the CDI tranche, will receive 250,000 CDI warrants.

Anteris Technologies Global Corp. (AVR) announced it will hold its first Annual Meeting of Stockholders on December 3, 2025 (December 4, 2025 in Australia). Stockholders of record as of October 30, 2025 (October 31, 2025 in Australia) will be entitled to vote.

Stockholder proposals for inclusion in the proxy materials under Rule 14a-8 must be received by the Company’s Secretary no later than October 25, 2025 at 11:59 p.m. Eastern time (2:59 p.m. AEDT on October 26, 2025 in Australia) and must comply with SEC rules, Delaware law, and the Company’s Amended and Restated Bylaws. Additional details, including exact time and matters to be voted on, will appear in the forthcoming proxy statement.

Anteris Technologies Global Corp. announced it obtained its first European regulatory clearance to commence the DurAVR Transcatheter Heart Valve Global Trial. The company furnished a press release as Exhibit 99.1.

This clearance permits initiation of the DurAVR clinical program in Europe. The information was furnished, not filed, under the Exchange Act and is not incorporated into other securities filings unless specifically referenced.

Anteris Technologies Global Corp. disclosed that after the FDA reviewed its Investigational Device Exemption (IDE) for the DurAVR^® THV System, the agency requested additional information focused mainly on bench testing. The company says it has submitted a formal response addressing those requests. The IDE package submitted includes the clinical study protocol and a technology package that the company states demonstrates the device has been developed and tested for a global pivotal trial. In parallel, Anteris is pursuing regulatory submissions with competent authorities in Europe to advance the PARADIGM Trial across multiple regions.

Documented by the company’s Vice Chairman and CEO, the filing reports regulatory engagement but does not disclose timelines, specific test results, or projected trial start dates.

Anteris Technologies Global Corp. filed a report describing a change in timing for a key shareholder event. On September 19, 2025, the company announced via press release that its Special Meeting of Stockholders has been adjourned and rescheduled to Monday, September 29, 2025 at 8:00 a.m. Central time, which corresponds to 11:00 p.m. AEST the same day.

The company also sent a formal Notice of Adjournment of Special Meeting of Stockholders to stockholders of record as of the Special Meeting’s record date. Both the press release and the notice are included as exhibits to the report, giving investors access to the official details about the new meeting date and time.

Anteris Technologies Global Corp. filed a current report to let investors know that its upcoming Special Meeting of Stockholders has been postponed. The meeting, which had been scheduled earlier, is now set for Thursday, September 18, 2025, at 5:00 p.m. Central time, which corresponds to 8:00 a.m. AEST on Friday, September 19, 2025. The company announced this change through a press release dated September 11, 2025.

The press release explaining the postponement is included as Exhibit 99.1, and the report also includes the cover page interactive data file as Exhibit 104. No financial results or transaction details are discussed in this report; it is focused on the timing of the stockholder meeting.

Anteris Technologies Global Corp. (AVR) filed a Form 8-K reporting a material event and attached a press release as Exhibit 99.1 dated September 4, 2025. The filing identifies the company as a Delaware corporation listed on The Nasdaq Global Market, provides the registrant's principal office address in Toowong, Queensland, Australia, and shows the company has elected emerging growth company status on the cover page. The 8-K cover also includes the Inline XBRL cover page flag and is signed by the company’s Vice Chairman and Chief Executive Officer, Wayne Paterson.